According to Fortune Business Insights, the global cancer biomarkers market was valued at USD 38.14 billion in 2024 and is projected to grow from USD 42.87 billion in 2025 to USD 74.62 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.2% during the forecast period. In 2024, North America dominated the market with a 35.99% share.
